Table 2.

Studies included in this analysis grouped by system organ class, treatment modality, number of SNVs and related MIADEs

System Organ Class	Endocrine agent & variants (n)	Adverse effects	Studies (n)	References
Musculoskeletal disorders	Tamoxifen (n = 7), Aromatase Inhibitors (n = 18)	BMDa, T-scorea, Bone fractures, Osteoporosisa, MS-ADEs	(n = 10)	15,16,18,20,23,25–28,33
Metabolism disorders	Tamoxifen (n = 2), Aromatase Inhibitors (n = 11)	Hypercholesterolaemiaa, Hypertriglyceridaemiaa	(n = 3)	19,24,34
Hepatobiliary disorders	Tamoxifen (n = 4)	Hepatosteatosis	(n = 2)	21,29
Vascular disorders	Tamoxifen (n = 3)	Thromboembolic events (incl. DVT, PE)	(n = 3)	22,32,35
Reproductive system disorders	Tamoxifen (n = 4), Aromatase Inhibitors (n = 1)	Endometrial cancer, Endometrial Hyperplasia	(n = 5)	14,17,30,31,34
Psychiatric disorders	Tamoxifen (n = 3)	Depression	(n = 1)	13

^aContinuous measurements or binary outcomes derived from baseline measurements.